FindTrial
Sign In

Does the use of nizatidine (Tazac) as a prokinetic agent improve gastric emptying in patients who have had an oesophagectomy for oesophageal cancer?

Does the use of nizatidine (Tazac) as a prokinetic agent improve gastric emptying in patients who have had an oesophagectomy for oesophageal cancer?

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12605000454673
Enrollment
20
Registered
2005-09-21
Start date
2004-12-01
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The purpose of this project is to see whether nizatidine, a drug commonly used to treat peptic ulcers and reflux disease, may improve the emptying of the stomach in patients who have had an operation for oesophageal cancer. Participation in this project involves taking the trial medication for one week and having a special gastric empyting scan before and after one week of treatment with the drug. The scan involves a small dose of radiation which has been approved by the Department of Human Services, Radiation Safety Approval.

Interventions

None listed

Sponsors

Cabrini Clinical Education and Research Institute
Lead SponsorOther

Study design

Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

6 months or more post oesophagectomy- written consent.

Exclusion criteria

Allergy to nizatidine- patients undergoing further treatment for oesophageal cancer- patients who are mentally or legally incapacitated- all pregnant women or potentially pregnant women.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026